维普中文期刊产品整合服务
72篇 您的检索式:作者名="DARREN L"
    题名 作者 年代 出处 被引量
1Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016显示文摘Portal vein tumor thrombosis(PVTT) is a common phenomenon in hepatocellular carcinoma(HCC). Compared to HCC without PVTT, HCC with PVTT is characterized by an aggressive disease course, worse hepatic function, a higher chance of complications related to portal hypertension and poorer tolerance to treatment. Conventionally, HCC with PVTT is grouped together with metastatic HCC during the planning of its management, and most patients are offered palliative treatment with sorafenib or other systemic agents. As a result, most data on the management of HCC with PVTT comes from subgroup analyses or retrospective series. In the past few years, there have been several updates on management of HCC with PVTT. First, it is evident that HCC with PVTT consists of heterogeneous subgroups with different prognoses. Different classifications have been proposed to stage the degree of portal vein invasion/thrombosis, suggesting that different treatment modalities may be individualized to patients with different risks. Second, more studies indicate that more aggressive treatment, including surgical resection or locoregional treatment, may benefit select HCC patients with PVTT. In this review, we aim to discussthe recent conceptual changes and summarize the data on the management of HCC with PVTT.Stephen L Chan Charing CN Chong Anthony WH Chan Darren MC Poon Kenneth SH Chok 2016World Journal of Gastroenterology2016,22,32:44
2Surgical ampullectomy:A comprehensive review显示文摘Tumours of the ampulla of Vater are relatively uncommon lesions of the digestive system.They are typically diagnosed at an earlier stage than other types of tumours in this region,due to their tendency to invoke symptoms by obstructing the bile duct or pancreatic duct.Consequently,many are potentially curable by excision.Surgical ampullectomy(SA)(or transduodenal ampullectomy)for an ampullary tumour was first described in 1899,but was soon surpassed by pancreatoduodenectomy(PD),which offered a more extensive resection resulting in a lower risk of recurrence.Ongoing innovation in endoscopic techniques over recent decades has led to the popularization of endoscopic papillectomy(EP),particularly for adenomas and even early cancers.The vast majority of resectable ampullary tumours are now treated using either PD or EP.However,SA continues to play a role in specific circumstances.Many authors have suggested specific indications for SA based on their own data,practices,or interpretations of the literature.However,certain issues have attracted controversy,such as its use for early ampullary cancers.Consequently,there has been a lack of clarity regarding indications for SA,and no evidence-based consensus guidelines have been produced.All studies reporting SA have employed observational designs,and have been heterogeneous in their methodologies.Accordingly,characteristics of patients and their tumours have differed substantially across treatment groups.Therefore,meaningful comparisons of clinical outcomes between SA,PD and EP have been elusive.Nevertheless,it appears that suitably selected cases of ampullary tumours subjected to SA may benefit from favourable peri-operative and long-term outcomes with very low mortality and significantly long survival,hence its role in this setting warrants further clarification,while it can also be useful in the management of specific benign entities.Whilst the commissioning of a randomised controlled trial seems unlikely,well-designed observational studies incorporating adjustments for confounding variables may become the best available comparative evidence for SA,potentially informing the eventual development of consensus guidelines.In this comprehensive review,we explore the role of SA in the modern management of ampullary lesions.Darren L Scroggie Vasileios K Mavroeidis 2021World Journal of Gastrointestinal Surgery2021,13,11:2
3A distributed industrial battery manage- ment network 显示文摘DARREN L ADNAN A 2004IEEE Transactions on Industrial Electronics2004,51,6:1
4A distributed industrial battery manage-ment network 显示文摘DARREN L ADNAN A 2004IEEE Transactions on Industrial HIcctronics2004,51,6:1
5Impact of prolonged sludge retention time on the per- formance of a submerged membrane bioreactor显示文摘Darren l)elai Sun Swee Loong Khor Choon Teck Hay 2007De- salination2007,208,13:1
6Vascular smooth muscle cells derived from atherosclerotic human arteries exhibit greater adhesion, migration, and proliferation than venous cells显示文摘Peter L Darren I Mark C 2002J Surg Res2002,104,:1
7Separation of dimethyl carbonate/methanol/water mixtures by pervaporation using crosslinked chitosan membranes显示文摘Wooyoung W Xianshe F Darren L 2003Sep Pur Technol2003,31,2:1
8Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases显示文摘 Wenbiao L Darren WD 2000Cancer2000,89,:1
9Pervaporation with chitosan membranes: separation of dimethyl carbonate/ methanol/water mixtures 显示文摘Wooyoung W Xianshe F Darren L 2002J Membr Sci2002,209,2:1
10Tracking with vir- tual slides: a tool to study diagnostic error in histopathol- ogy显示文摘Darren T Chee H L Derek M 2009Histopathology2009,55,1:1
11Tetrazine Explosives显示文摘David E Chavez Michael A Hiskey Darren L Naud 2004Propellants Explosives Pyrotechnics2004,29,4:1
12Characterization of mucosal and systemic immune responses in rainbow trout (Oncorhynchus mykiss) using surface plasmon response 显示文摘Remeth D C Darren R J Robert L R 2000Fish Shellfish Immunol2000,10,:1
13An assessment of flood emergency plans in England and Wales, France and the Neth- erlands显示文摘Darren L Karin S Freddy V(2011 ) 2011Natural Hazards2011,58,:1
14Outcomes following liver transplantation in intensive care unit patients显示文摘AIM:To determine feasibility of liver transplantation in patients from the intensive care unit (ICU) by estimating graft and patient survival.METHODS:This single center retrospective study included 39 patients who had their first liver transplant directly from the intensive care unit and 927 non-ICU patients who were transplanted from hospital ward or home between January 2005 and December 2010.RESULTS:In comparison to non-ICU patients,ICU patients had a higher model for end-stage liver disease (MELD) at transplant (median:37 vs 20,P < 0.001).Fourteen out of 39 patients (36%) required vasopressor support immediately prior to liver transplantation (LT) with 6 patients (15%) requiring both vasopressin and norepinephrine.Sixteen ICU patients (41%) were ventilator dependent immediately prior to LT with 9 patients undergoing percutaneous tracheostomy prior to transplantation.Twenty-five ICU patients (64%) required dialysis preoperatively.At 1,3 and 5 years after LT,graft survival was 76%,68% and 62% in ICU patients vs 90%,81% and 75% in non-ICU patients.Patient survival at 1,3 and 5 years after LT was 78%,70% and 65% in ICU patients vs 94%,85% and 79% in non-ICU patients.When formally comparing graft survival and patient survival between ICU and nonICU patients using Cox proportional hazards regression models,both graft survival [relative risk (RR):1.94,95%CI:1.09-3.48,P=0.026] and patient survival (RR:2.32,95%CI:1.26-4.27,P=0.007) were lower in ICU patients vs non-ICU patients in single variable analysis.These findings were consistent in multivariable analysis.Although not statistically significant,graft survival was worse in both patients with cryptogenic cirrhosis (RR:3.29,P=0.056) and patients who received donor after cardiac death (DCD) grafts (RR:3.38,P=0.060).These findings reached statistical significance when considering patient survival,which was worse for patients with cryptogenic cirrhosis (RR:3.97,P=0.031) and patients who were transplanted with DCD livers (RR:4.19,P=0.033).Graft survival and patient survival were not significantly worse for patients on mechanical ventilation (RR:0.91,P=0.88 in graft loss;RR:0.69,P=0.56 in death) or patients on vasopressors (RR:1.06,P=0.93 in graft loss;RR:1.24,P=0.74 in death) immediately prior to LT.Trends toward lower graft survival and patient survival were observed for patients on dialysis immediately before LT,however these findings did not approach statistical significance (RR:1.70,P=0.43 in graft loss;RR:1.46,P=0.58 in death).CONCLUSION:Although ICU patients when compared to non-ICU patients have lower survivals,outcomes are still acceptable.Pre-transplant ventilation,hemodialysis,and vasopressors were not associated with adverse outcomes.Lena Sibulesky Michael G Heckman C Burcin Taner Juan M Canabal Nancy N Diehl Dana K Perry Darren L Willingham Surakit Pungpapong Barry G Rosser David J Kramer Justin H Nguyen 2013World Journal of Hepatology2013,5,1:1
15Neural development of selective attention and response inhibition显示文摘James R Booth Douglas D Burman Joel R Meyer Zhang Lei Barbara L Trommer Nicholas D Davenport Wei Li Todd B Parrish Darren R Gitelman M.Marsel Mesulam 2003Neuroimage2003,,2:1
16Targeted disruption of the murine CCK-1 receptor gene reduces intestinal lipid-induced feedback inhibition of gastric function显示文摘 Darren T Kent L 2006Am J Physiol Gastrointest Liver Physiol2006,290,:1
17Separation mixtures by pervaporation using crossliiaked chitosan membranes显示文摘WOOYOUNG W XIANSHE F DARREN of dimethyl carbo L 2003Separation and Purification Technology2003,31,2:1
18Separation of dimethyl carbonate/methanol/water mixtures by pervaporation using crosslinked chitosan membranes显示文摘Wooyoung W Xianshe F Darren L 2003Separation and Purification Technology2003,31,2:1
19Pervaporation with chitosan membranes: separation of dimethyl carbonate/methanol/water mixtures 显示文摘WOOYOUNG W XIANSHE F DARREN L 2002Journal of Membrane Science2002,209,2:1
20Pervaporation with chitosan membranes:separation of dimethyl carbonate/methanol/water mixtures显示文摘Wooyoung W Xianshe F Darren L 2002Journal of Membrane Science2002,209,2:1
返回顶部 每页显示:
共4页 首页 上一页 第1页 下一页 末页 /4 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费